NewAmsterdam Pharma (NASDAQ:NAMS - Get Free Report) major shareholder Nap B.V. Forgrowth sold 100,728 shares of the firm's stock in a transaction on Wednesday, December 18th. The stock was sold at an average price of $26.10, for a total transaction of $2,629,000.80. Following the completion of the transaction, the insider now directly owns 10,908,502 shares of the company's stock, valued at approximately $284,711,902.20. This represents a 0.91 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Major shareholders that own at least 10% of a company's stock are required to disclose their transactions with the SEC.
Nap B.V. Forgrowth also recently made the following trade(s):
- On Thursday, December 12th, Nap B.V. Forgrowth sold 166,011 shares of NewAmsterdam Pharma stock. The stock was sold at an average price of $25.39, for a total value of $4,215,019.29.
- On Monday, November 18th, Nap B.V. Forgrowth sold 33,273 shares of NewAmsterdam Pharma stock. The shares were sold at an average price of $25.08, for a total value of $834,486.84.
- On Friday, November 15th, Nap B.V. Forgrowth sold 8,530 shares of NewAmsterdam Pharma stock. The shares were sold at an average price of $25.02, for a total value of $213,420.60.
NewAmsterdam Pharma Price Performance
Shares of NewAmsterdam Pharma stock opened at $25.50 on Friday. NewAmsterdam Pharma has a 12 month low of $10.50 and a 12 month high of $27.29. The business has a 50 day simple moving average of $21.31 and a two-hundred day simple moving average of $18.95.
Analysts Set New Price Targets
Nvidia’s Bold Move: Tackling Tech’s $1 Trillion Crisis
From Weiss Ratings | Ad
Taiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as 4,744%.
Now, if you’re like everybody else, you want to know what Nvidia’s doing next … and who they’re going to partner with …
Find out details on these three critical Nvidia partners immediately.
Several analysts have commented on NAMS shares. Needham & Company LLC restated a "buy" rating and set a $36.00 price objective on shares of NewAmsterdam Pharma in a research note on Thursday, December 5th. Piper Sandler restated an "overweight" rating and issued a $37.00 price target on shares of NewAmsterdam Pharma in a research note on Monday, September 23rd. Royal Bank of Canada reissued an "outperform" rating and issued a $31.00 price objective on shares of NewAmsterdam Pharma in a report on Thursday, September 5th. Finally, Scotiabank upped their target price on NewAmsterdam Pharma from $35.00 to $47.00 and gave the stock a "sector outperform" rating in a research note on Wednesday, December 11th. Six research analysts have rated the stock with a buy rating, According to MarketBeat.com, NewAmsterdam Pharma presently has a consensus rating of "Buy" and an average target price of $36.20.
Check Out Our Latest Stock Analysis on NAMS
Hedge Funds Weigh In On NewAmsterdam Pharma
Hedge funds and other institutional investors have recently modified their holdings of the business. Frazier Life Sciences Management L.P. lifted its stake in NewAmsterdam Pharma by 5.1% in the 3rd quarter. Frazier Life Sciences Management L.P. now owns 12,855,194 shares of the company's stock worth $213,396,000 after purchasing an additional 628,251 shares in the last quarter. Janus Henderson Group PLC increased its position in NewAmsterdam Pharma by 51.1% during the third quarter. Janus Henderson Group PLC now owns 1,540,729 shares of the company's stock worth $25,607,000 after purchasing an additional 520,772 shares during the last quarter. Millennium Management LLC raised its stake in NewAmsterdam Pharma by 23.0% during the second quarter. Millennium Management LLC now owns 1,165,429 shares of the company's stock worth $22,388,000 after purchasing an additional 217,902 shares during the period. Jennison Associates LLC boosted its holdings in NewAmsterdam Pharma by 8.9% in the 3rd quarter. Jennison Associates LLC now owns 1,020,278 shares of the company's stock valued at $16,937,000 after purchasing an additional 83,115 shares during the last quarter. Finally, Deerfield Management Company L.P. Series C grew its stake in shares of NewAmsterdam Pharma by 30.3% in the 2nd quarter. Deerfield Management Company L.P. Series C now owns 869,250 shares of the company's stock valued at $16,698,000 after buying an additional 202,250 shares during the period. 89.89% of the stock is owned by hedge funds and other institutional investors.
NewAmsterdam Pharma Company Profile
(
Get Free Report)
NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
